1-(2,4-二氟苯基)-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸 | 100490-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1-(2,4-二氟苯基)-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸
• 英文名称: A 57274
• 英文别名: 1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydronaphthyridine-3-carboxylic acid；1-o,p-difluorophenyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid；1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid；1,8-Naphthyridine-3-carboxylic acid, 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-；1-(2,4-difluorophenyl)-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
• CAS: 100490-19-5
• 化学式: C₁₉H₁₅F₃N₄O₃
• 分子量: 404.348
• InChiKey: CVAQZAKLVQJAQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  hexamethylene bis(cyanoguanidine) 、 1-(2,4-二氟苯基)-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸 在 盐酸 作用下， 以 水 、 正丁醇 为溶剂， 反应 106.0h， 以0.3 g的产率得到7-[4-[N'-[N'-[6-[[amino-[[amino-[4-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-1,8-naphthyridin-2-yl]piperazin-1-yl]methylidene]amino]methylidene]amino]hexyl]carbamimidoyl]carbamimidoyl]piperazin-1-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
  参考文献：
  名称：

  ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS

  摘要：

  本文披露了具有抗病毒和抗菌活性的胍和双胍衍生物。还披露了含有这些化合物作为活性成分的药物组合物，以及利用这些化合物的抗病毒和抗菌方法。还披露了使用胍和双胍衍生物治疗感染的方法。

  公开号：

  US20140073631A1
• 作为产物：
  描述：

  1-(2,4-二氟苯基)-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸乙酯 在 甲醇 、 sodium hydroxide 、 水 、 柠檬酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 1-(2,4-二氟苯基)-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸
  参考文献：
  名称：

  [EN] RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES
  [FR] DERIVES DE RIFAMYCINE EFFICACES CONTRE DES MICROBES PHARMACORESISTANTS

  摘要：

  公开号：

  WO2005070940A3

文献信息

• [EN] RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES<br/>[FR] DERIVES DE RIFAMYCINE IMINO EFFICACES CONTRES DES MICROBES PHARMACORESISTANTS
  申请人：CUMBRE INC

  公开号：WO2005070941A1

  公开（公告）日：2005-08-04

  The present invention relates to rifamycin 3-iminomethylenyl (-CH=N-) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (-CH=N-) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(-CH=N-)衍生物，包括对耐药微生物的活性。所述的利福霉素衍生物具有一个利福霉素基团，通过亚甲基亚胺基(-CH=N-)在利福霉素基团的C-3碳上与一个连接剂共价连接，而连接剂又与DNA旋转酶和拓扑异构酶IV抑制剂家族中的奎诺酮结构或其药效团共价连接。这种创新的利福霉素是新颖的，并对利福平和环丙沙星耐药微生物表现出活性。
• NOVEL METHOD OF SYNTHESIS OF FLUOROQUINOLONES
  申请人：BERTHON-CEDILLE Laurence

  公开号：US20090054643A1

  公开（公告）日：2009-02-26

  The invention relates to a method of preparation of fluoroquinolones of formula (I) from compounds of formula (II): in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and X are as defined in Claim 1.

  该发明涉及一种从化合物（II）制备化合物（I）的氟喹诺酮的方法：其中R1、R2、R3、R4、R5、R6、R7和X的定义如权利要求1中所述。
• Naphthyridine antibacterial compounds
  申请人：Abbott Laboratories

  公开号：US04616019A1

  公开（公告）日：1986-10-07

  Naphthyridine compounds having the formula: ##STR1## wherein Z is an amine or an aliphatic heterocyclic group, R is a phenyl group or an aromatic heterocyclic group and R.sub.1 is hydrogen or a carboxy protecting group. The compounds of the invention have antibacterial activity.

  具有以下式子的萘啶化合物：##STR1## 其中Z是胺基或脂肪族杂环基，R是苯基或芳香族杂环基，R.sub.1是氢或羧基保护基。本发明的化合物具有抗菌活性。
• Rifamycin derivatives effective against drug-resistant microbes
  申请人：Ma Zhenkun

  公开号：US20050261262A1

  公开（公告）日：2005-11-24

  Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

  本发明涉及具有抗微生物活性的利福霉素衍生物，包括对耐药微生物的活性。本发明的利福霉素衍生物独特地设计在于，它们具有利福霉素基团通过利福霉素基团的C-3碳与连接基团共价连接，并且连接基团进一步与治疗性基团或抗菌剂/药效团共价连接。治疗性基团可以是喹诺酮、噁唑烷酮、大环内酯、氨基糖苷、四环素核心或与抗菌剂相关的结构/药效团。
• Rifamycin imino derivatives effective against drug-resistant microbes
  申请人：Ding Z. Charles

  公开号：US20050209210A1

  公开（公告）日：2005-09-22

  The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

  本发明涉及具有抗微生物活性的利福霉素3-亚甲基亚胺基(—CH═N—)衍生物，包括对耐药微生物的活性。所述利福霉素衍生物具有利福霉素基团通过亚甲基亚胺基(—CH═N—)与连接基团共价连接于利福霉素基团的C-3碳，并且连接基团与DNA酶解酶和拓扑异构酶IV抑制剂家族中的喹诺酮结构或其药效团共价连接。本发明的利福霉素是新颖的，并且对利福平和环丙沙星耐药微生物均有活性。